Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Complement Therapeutics
United Kingdom
- London
- 18/04/2023
- Series A
- $78,929,000
Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
- Industry Biotechnology
- Website https://complementtx.com/
- LinkedIn https://www.linkedin.com/company/complement-therapeutics/
Related People
Rafiq HasanFounder
United Kingdom -
West Ealing, England
Proven track record of leading global cross-functional commercial teams to deliver year on year sales growth, managing multi-billion dollar global franchises. A unique combination of in-depth commercial, medical, market access and P&L experience. Passionate about medtech and innovation, mentoring start-ups at Wayra and through the UK Clinical Entrepreneurship Programme.
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)